Founder’s Vision
ANKTIVA®
BCG
Clinical Trials
Find a Trial
Become a Trial
Investigator
License our Cells
Science
Platforms
Pipeline
Expanded Access
Research
Approach
Patients
Trial Investigators
Researchers
Condition
Bladder Cancer
Glioblastoma
HIV
Lynch / Colon Cancer
Non-Hodgkin Lymphoma
Ovarian Cancer
Human Papillomavirus
Non-Small Cell Lung Cancer
Company
About Us
News & Events
Careers
Investors
Contact
Select Page
Acceptance Requirements
Adult patients diagnosed with CD19 and CD20-positive B-cell non-Hodgkin lymphoma
Have completed two lines of chemotherapy
Search for:
Recent Posts
Jefferies Global Healthcare Conference 2025
ImmunityBio, Saudi Arabia’s Ministry of Investment, KFSHRC, and KAIMRC Sign Strategic Memorandum of Understanding to Launch Cancer BioShield
TM
Platform in the Middle East
ImmunityBio Reports Doubled Net Revenue and 150% Unit Growth in Q1 2025, With Continued Strong Sales Momentum in First Quarter since J-code
ImmunityBio Requests an Urgent Meeting With FDA to Address the Change in the Agency’s Unambiguous Guidance on Jan 2025 to Submit a sBLA for NMIBC BCG Unresponsive Papillary Disease, Following an Inconsistent Refusal to File Letter on May 2, 2025
Unmatched Long-Term Bladder Preservation for 36 Months in over 80 percent of Responders with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC CIS and Papillary Disease Alone – Best in Disease and Best in Class with 5 Year Follow-Up
